- France
- /
- Healthtech
- /
- ENXTPA:EQS
Investors Appear Satisfied With Equasens Société anonyme's (EPA:EQS) Prospects As Shares Rocket 33%
The Equasens Société anonyme (EPA:EQS) share price has done very well over the last month, posting an excellent gain of 33%. Unfortunately, the gains of the last month did little to right the losses of the last year with the stock still down 20% over that time.
Following the firm bounce in price, Equasens Société anonyme may be sending bearish signals at the moment with its price-to-earnings (or "P/E") ratio of 20.8x, since almost half of all companies in France have P/E ratios under 15x and even P/E's lower than 10x are not unusual. Nonetheless, we'd need to dig a little deeper to determine if there is a rational basis for the elevated P/E.
While the market has experienced earnings growth lately, Equasens Société anonyme's earnings have gone into reverse gear, which is not great. One possibility is that the P/E is high because investors think this poor earnings performance will turn the corner. If not, then existing shareholders may be extremely nervous about the viability of the share price.
Check out our latest analysis for Equasens Société anonyme
Does Growth Match The High P/E?
There's an inherent assumption that a company should outperform the market for P/E ratios like Equasens Société anonyme's to be considered reasonable.
Retrospectively, the last year delivered a frustrating 23% decrease to the company's bottom line. This means it has also seen a slide in earnings over the longer-term as EPS is down 7.5% in total over the last three years. Accordingly, shareholders would have felt downbeat about the medium-term rates of earnings growth.
Shifting to the future, estimates from the four analysts covering the company suggest earnings should grow by 16% per annum over the next three years. That's shaping up to be materially higher than the 13% each year growth forecast for the broader market.
In light of this, it's understandable that Equasens Société anonyme's P/E sits above the majority of other companies. It seems most investors are expecting this strong future growth and are willing to pay more for the stock.

The Final Word
Equasens Société anonyme shares have received a push in the right direction, but its P/E is elevated too. Using the price-to-earnings ratio alone to determine if you should sell your stock isn't sensible, however it can be a practical guide to the company's future prospects.
We've established that Equasens Société anonyme maintains its high P/E on the strength of its forecast growth being higher than the wider market, as expected. Right now shareholders are comfortable with the P/E as they are quite confident future earnings aren't under threat. It's hard to see the share price falling strongly in the near future under these circumstances.
The company's balance sheet is another key area for risk analysis. Our free balance sheet analysis for Equasens Société anonyme with six simple checks will allow you to discover any risks that could be an issue.
Of course, you might find a fantastic investment by looking at a few good candidates. So take a peek at this free list of companies with a strong growth track record, trading on a low P/E.
Valuation is complex, but we're here to simplify it.
Discover if Equasens Société anonyme might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About ENXTPA:EQS
Equasens Société anonyme
Provides healthcare IT solutions in Europe.
Flawless balance sheet, undervalued and pays a dividend.
Similar Companies
Market Insights
Weekly Picks

Is this the AI replacing marketing professionals?
Pro Medicus: The Market Is Confusing a Lumpy Quarter With a Broken Business
The Rising Deal Risk That Helped Sink Netflix’s $72 Billion Bid for Warner Bros. Discovery
The Infrastructure AI Cannot Be Built Without
Recently Updated Narratives

A case for Ridgeline Minerals: Base case CAD$2.00, Bull case CAD$5.00+
CSL: The Dip Is the Opportunity
Apple will shine with a 6% revenue growth in the next 5 years
Popular Narratives
Nu holdings will continue to disrupt the South American banking market

NVDA: Expanding AI Demand Will Drive Major Data Center Investments Through 2026
